Glaucoma Therapeutics Market
Glaucoma Therapeutics Strategic Industry Report 2024 - Growth in Specialty Eye Clinics Enhancing Treatment Reach
December 09, 2024 11:03 ET | Research and Markets
Dublin, Dec. 09, 2024 (GLOBE NEWSWIRE) -- The "Glaucoma Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Glaucoma...
Figures PR 0612
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
December 06, 2024 16:03 ET | NurExone Biologic Inc
NurExone announces significant findings from a preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing Optic Nerve Damage (OND)
22157.jpg
Mydriasis Epidemiology Forecast Report 2020-2034
December 02, 2024 04:43 ET | Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Mydriasis - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.For the purpose of designing the patient-based...
DMR Logo.png
Ophthalmic Devices Market Is Expected To Reach Revenue Of USD 120.3 Bn By 2033, At 5.1% CAGR: Dimension Market Research.
October 01, 2024 14:01 ET | Dimension Market Research
New York, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Market Overview The Global Ophthalmic Devices Market is projected to reach USD 76.9 billion in 2024 and is expected to grow to USD 120.3 billion by...
22157.jpg
Evolving Landscape of Open-Angle Glaucoma Pipeline Therapies in 2024
September 25, 2024 04:12 ET | Research and Markets
Dublin, Sept. 25, 2024 (GLOBE NEWSWIRE) -- The "Open-Angle Glaucoma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.A comprehensive analytical report has been...
Electroretinogram (ERG) measurements
Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
July 17, 2024 16:14 ET | NurExone Biologic Inc
TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
Optic Nerve Regeneration - research team
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
June 28, 2024 16:04 ET | NurExone Biologic Inc
Prestigious Eye Institute Exploring New Indication for NurExone’s ExoPTEN
Global Ophthalmic Eye Dropper Market
Global Ophthalmic Eye Droppers Market Report 2024: A $25.88 Billion Opportunity by 2034 with Regional and Country-Level Data for Types, Drugs, Treatments, and End-users
March 12, 2024 12:13 ET | Research and Markets
Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "Global Ophthalmic Eye Dropper Market by Type, by Drug Type, by Treatment Type, by End-user, and By Region" report has been added to ...
Transparency Market Research
Glaucoma Treatment Market Set to Surge at 4.3% CAGR, to Reach USD 9.1 billion by 2031 | Transparency Market Research, Inc.
December 19, 2023 03:41 ET | Transparency Market Research
Wilmington, Delaware, United States, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The glaucoma treatment market was valued at US$ 6.3 billion in 2022. A CAGR of 4.3% is...
22157.jpg
Ocular Hypertension Pipeline Research Report 2023: Comprehensive Insights About 70+ Companies and 75+ Pipeline Drugs
November 24, 2023 05:43 ET | Research and Markets
Dublin, Nov. 24, 2023 (GLOBE NEWSWIRE) -- The "Ocular Hypertension - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.This "Ocular Hypertension - Pipeline...